Skip to main content
. 2015 Nov 12;2015:838652. doi: 10.1155/2015/838652

Figure 4.

Figure 4

Effect of the HER2 inhibitor trastuzumab on HB4a and Hb4aC5.2 cells. (a) Relative expression of FAT/CD36, FABP4, DGAT, FASN, SREBP1, and LIPIN1 in HB4a and HB4aC5.2 cells treated with trastuzumab (Herceptin, 15 μg/mL for 72 h) or PBS as a control (CNT). Data were obtained from an experiment performed in quadruplicate. The real-time PCR reaction was performed in duplicate. ∗ P < 0.001 versus CNT. (b) Proliferation rates of HB4a and HB4aC5.2 cells treated with trastuzumab (TRAST) or PBS as a control (CNT) for 0, 12, 24, 48, and 72 h. ∗ P < 0.001 versus HB4aC5.2 CNT. ∗∗ P < 0.001 versus HB4aC5.2 TRAST.